Mukherjee, Soumya <br/><br/>
Craniotomy for recurrent glioblastoma: Is it justified? A comparative cohort study with outcomes over 10 years.  [electronic resource] 

 -  Clinical neurology and neurosurgery  01 2020 
 - 105568 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1872-6968 
<br/><br/><label>Standard No.: </label>10.1016/j.clineuro.2019.105568  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Age Factors<br/>Aged<br/>Antineoplastic Agents, Alkylating--therapeutic use<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Bevacizumab--therapeutic use<br/>Brain Neoplasms--physiopathology<br/>Chemoradiotherapy<br/>Chemoradiotherapy, Adjuvant<br/>Chemotherapy, Adjuvant<br/>Cohort Studies<br/>Craniotomy<br/>DNA Methylation<br/>DNA Modification Methylases--genetics<br/>DNA Repair Enzymes--genetics<br/>Female<br/>Glioblastoma--physiopathology<br/>Humans<br/>Kaplan-Meier Estimate<br/>Karnofsky Performance Status<br/>Lomustine--therapeutic use<br/>Male<br/>Middle Aged<br/>Neoplasm Recurrence, Local--physiopathology<br/>Neurosurgical Procedures<br/>Promoter Regions, Genetic<br/>Proportional Hazards Models<br/>Prospective Studies<br/>Quality of Life<br/>Radiotherapy<br/>Radiotherapy, Adjuvant<br/>Reoperation<br/>Survival Rate<br/>Temozolomide--therapeutic use<br/>Tumor Suppressor Proteins--genetics<br/>Young Adult